Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

IFM Therapeutics

Request full access

A biopharmaceutical company developing a portfolio of first-in-class small molecules targeting the innate immune system

Boston, United StatesFounded 2015Biotech & Life Sciences

About IFM Therapeutics

IFM Therapeutics is a biopharmaceutical startup that specializes in the development of first-in-class medicines aimed at controlling or enhancing immune responses for the treatment of inflammation-driven diseases and cancer. The company operates in the pharmaceutical market, serving a broad range of clients, including patients suffering from these conditions and other healthcare stakeholders.

The company's business model revolves around the discovery and development of novel drugs. It has a strong track record, with three novel programs progressing from inception to the clinic within the first 3.5 years. The company has also successfully closed two major deals, demonstrating its financial viability and growth potential.

IFM Therapeutics has made significant strides in its research and development efforts. It has identified novel and proprietary NLRP3 and STING agonists, which are molecules that bind to a protein and activate it, potentially leading to a therapeutic effect in the body. The company has also demonstrated preclinical proof of concept for both these agonists.

The company has secured substantial funding, closing a $27M Series A round and a $31M Series A financing for its subsidiary, IFM Tre. It has also successfully sold two of its entities, IFM Uno and IFM Tre, for $2.32B and $1.575B respectively, further bolstering its financial position.

Currently, IFM Therapeutics is conducting various clinical trials, including Phase 2 trials investigating the use of its NLRP3 antagonist, IFM-2427, in treating familial cold auto-inflammatory syndrome and symptomatic knee osteoarthritis, among other conditions.

Source: Dealroom company data

At a glance

Status
Acquired
Founded
2015
Headquarters
Boston, United States
Employees
12
Open positions
None listed
Dealroom signal
71.7/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCOther financing Dec 2019 $56M $222M Omega Funds · Atlas Venture —
SERIES AOther financing Jul 2018 $31M $124M Atlas Venture · Bristol-Myers Squibb —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

IFM Therapeutics website traffic

Latest recorded traffic for IFM Therapeutics is 2.9K monthly website visits, up 70.6% over the last three months. IFM Therapeutics's team declined 57.1% over the past year.

Latest monthly visits2.9K 3-month web change+70.6% 1-year team growth-57.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

IFM Therapeutics in the Boston ecosystem

Live from Dealroom

The IFM Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

Other known investors1 additional known investor

  • EPFL Swiss Federal Polytechnic School of Lausanne
Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States57.1%
🇩🇪 Germany42.9%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about IFM Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See IFM Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.